Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1971 Jun;34(3):219–223. doi: 10.1136/jnnp.34.3.219

Comparison of benefit from l-dopa in Parkinsonism with increase of amine metabolites in the CSF

R B Godwin-Austen 1,1, B D Kantamaneni 1, G Curzon 1
PMCID: PMC1083454  PMID: 5571307

Abstract

Homovanillic acid (HVA) and 5-hydroxy indole acetic acid (5-HIAA) concentrations have been estimated in the cerebrospinal fluid (CSF) of 16 and 18 patients respectively with Parkinsonism both before and during treatment with l-dopa. The rise of HVA correlated with dose of l-dopa. An increase of HVA concentration to less than 0·10 μg/ml. was associated with little or no clinical improvement. The five patients with the greatest increase of HVA concentration/g l-dopa showed little or no improvement from treatment and four of these patients had normal pre-treatment HVA and 5-HIAA. In those patients who responded well to l-dopa the CSF HVA/g l-dopa was intermediate between that of these two groups. It is suggested that change in HVA content of CSF during l-dopa treatment might be of value in the prediction of response to l-dopa.

Full text

PDF
219

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bernheimer H., Birkmayer W., Hornykiewicz O. Homovanillinsäure im Liquor cerebrospinalis: Untersuchungen beim Parkinson-Syndrom und anderen Erkrankungen des ZNS. Wien Klin Wochenschr. 1966 Jun 10;78(23):417–419. [PubMed] [Google Scholar]
  2. Calne D. B., Stern G. M., Spiers A. S., Laurence D. R. L-dopa in idiopathic parkinsonism. Lancet. 1969 Nov 8;2(7628):973–976. doi: 10.1016/s0140-6736(69)90536-4. [DOI] [PubMed] [Google Scholar]
  3. Constantinidis J., Bartholini G., Geissbühler F., Tissot R. La barrière capillaire enzymatique pour la DOPA au niveau de quelques noyaux du tronc cérébral du rat. Experientia. 1970 Apr 15;26(4):381–383. doi: 10.1007/BF01896900. [DOI] [PubMed] [Google Scholar]
  4. Cotzias G. C., Papavasiliou P. S., Gellene R. Modification of Parkinsonism--chronic treatment with L-dopa. N Engl J Med. 1969 Feb 13;280(7):337–345. doi: 10.1056/NEJM196902132800701. [DOI] [PubMed] [Google Scholar]
  5. Curzon G., Godwin-Austen R. B., Tomlinson E. B., Kantamaneni B. D. The cerebrospinal fluid homovanillic acid concentration in patients with Parkinsonism treated with L-dopa. J Neurol Neurosurg Psychiatry. 1970 Feb;33(1):1–6. doi: 10.1136/jnnp.33.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Eccleston D., Ashcroft G. W., Crawford T. B. Effect of tryptophan administration on 5HIAA in cerebrospinal fluid in man. J Neurol Neurosurg Psychiatry. 1970 Apr;33(2):269–272. doi: 10.1136/jnnp.33.2.269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Godwin-Austen R. B., Tomlinson E. B., Frears C. C., Kok H. W. Effects of L-dopa in Parkinson's disease. Lancet. 1969 Jul 26;2(7613):165–168. doi: 10.1016/s0140-6736(69)91417-2. [DOI] [PubMed] [Google Scholar]
  8. Goodwin F. K., Brodie H. K., Murphy D. L., Bunney W. E., Jr Administration of a peripheral decarboxylase inhibitor with L-dopa to depressed patients. Lancet. 1970 May 2;1(7653):908–911. doi: 10.1016/s0140-6736(70)91044-5. [DOI] [PubMed] [Google Scholar]
  9. Guldberg H. C., Turner J. W., Hanieh A., Ashcroft G. W., Crawford T. B., Perry W. L., Gillingham F. J. On the occurrence of homovanillic acid and 5-hydroxyindol-3-ylacetic acid in the ventricular C.S.F. of patients suffering from parkinsonism. Confin Neurol. 1967;29(2):73–77. doi: 10.1159/000103680. [DOI] [PubMed] [Google Scholar]
  10. Guldberg H. C., Yates C. M. Some studies of the effects of chlorpromazine, reserpine and dihydroxyphenylalanine on the concentrations of homovanillic acid, 3,4-dihydroxyphenylacetic acid and 5-hydroxyindol-3-ylacetic acid in ventricular cerebrospinal fluid of the dog using the technique of serial sampling of the cerebrospinal fluid. Br J Pharmacol Chemother. 1968 Jul;33(3):457–471. doi: 10.1111/j.1476-5381.1968.tb00494.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Johansson B., Roos B. E. 5-hydroxyindoleacetic and homovanillic acid levels in the cerebrospinal fluid of healthy volunteers and patients with Parkinson's syndrome. Life Sci. 1967 Jul 1;6(13):1449–1454. doi: 10.1016/0024-3205(67)90193-2. [DOI] [PubMed] [Google Scholar]
  12. Korf J., Valkenburgh-Sikkema T. Fluorimetric determination of 5-hydroxyindoleacetic acid in human urine and cerebrospinal fluid. Clin Chim Acta. 1969 Nov;26(2):301–306. doi: 10.1016/0009-8981(69)90383-0. [DOI] [PubMed] [Google Scholar]
  13. Mawdsley C. Treatment of Parkinsonism with Laevo-dopa. Br Med J. 1970 Feb 7;1(5692):331–337. doi: 10.1136/bmj.1.5692.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Olsson R., Roos B. E. Concentrations of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid after treatment with probenecid in patients with Parkinson's disease. Nature. 1968 Aug 3;219(5153):502–503. doi: 10.1038/219502a0. [DOI] [PubMed] [Google Scholar]
  15. Owman C., Rosengren E. Dopamine formation in brain capillaries--an enzymic blood-brain barrier mechanism. J Neurochem. 1967 May;14(5):547–550. doi: 10.1111/j.1471-4159.1967.tb09553.x. [DOI] [PubMed] [Google Scholar]
  16. Peaston M. J., Bianchine J. R. Metabolic studies and clinical observations during L-dopa treatment of Parkinson's disease. Br Med J. 1970 Feb 14;1(5693):400–403. doi: 10.1136/bmj.1.5693.400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Persson T., Roos B. E. Clinical and pharmacological effects of monoamine precursors or haloperidol in chronic schizophrenia. Nature. 1968 Mar 2;217(5131):854–854. doi: 10.1038/217854a0. [DOI] [PubMed] [Google Scholar]
  18. Weiner W., Harrison W., Klawans H. L-dopa and cerebrospinal fluid homovanillic acid in Parkinsonism. Life Sci. 1969 Sep 1;8(17):971–976. doi: 10.1016/0024-3205(69)90428-7. [DOI] [PubMed] [Google Scholar]
  19. Yahr M. D., Duvoisin R. C., Schear M. J., Barrett R. E., Hoehn M. M. Treatment of parkinsonism with levodopa. Arch Neurol. 1969 Oct;21(4):343–354. doi: 10.1001/archneur.1969.00480160015001. [DOI] [PubMed] [Google Scholar]
  20. van Woert M. H., Bowers M. B., Jr The effect of L-dopa on monoamine metabolites in Parkinson's disease. Experientia. 1970;26(2):161–163. doi: 10.1007/BF01895555. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES